Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Pasithea Therapeutics Corp
(NQ:
KTTA
)
3.800
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pasithea Therapeutics Corp
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
June 01, 2023
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END
Via
FinancialNewsMedia
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
December 07, 2022
From
CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
Via
Business Wire
Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics
November 22, 2022
From
CAMAC PARTNERS, LLC AND AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD. AND LEONITE CAPITAL LLC
Via
Business Wire
Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis
October 03, 2022
Learn More about Pasithea Therapeutics by gaining access to the latest research report
Via
TheNewswire.com
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics
October 13, 2022
From
Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via
Business Wire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
October 12, 2022
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide...
Via
FinancialNewsMedia
Exposures
COVID-19
Ron Bauer, Author of Exit Plan: How to Raise Money & Go Public, has a book release planned for December 2022
September 29, 2022
Via
Get News
Investor Group Sends Letter to Pasithea Therapeutics’ Board of Directors
September 28, 2022
From
Camac Partners, LLC and Affiliates of Concord Investment Partners Ltd. and Leonite Capital LLC
Via
Business Wire
Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics
September 06, 2022
From
Camac Partners, LLC, Affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via
Business Wire
Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting
August 24, 2022
From
CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC
Via
Business Wire
Global Multiple Sclerosis Drugs Market Size Projected To Reach $33 Billion By 2029
August 11, 2022
Palm Beach, FL –– August 11, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease affecting the central nervous system. It is characterized by...
Via
FinancialNewsMedia
Exposures
COVID-19
Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting
August 05, 2022
From
CAMAC PARTNERS, LLC, AFFILIATES OF CONCORD INVESTMENT PARTNERS LTD., AND LEONITE CAPITAL LLC.
Via
Business Wire
Investor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5
June 23, 2022
From
Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC
Via
Business Wire
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
June 22, 2022
Palm Beach, FL – June 22, 2022 – FinancialNewsMedia.com News Commentary Neuroinflammatory disorder is the study of conditions where immune responses which damage components of the nervous system. It...
Via
FinancialNewsMedia
PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article
May 05, 2022
Via
Investor Brand Network
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
March 08, 2022
Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric...
Via
FinancialNewsMedia
Topics
Economy
Exposures
Economy
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
February 03, 2022
Palm Beach, FL –– February 3, 2022 – FinancialNewsMedia.com News Commentary – Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system. It is characterized by demyelination,...
Via
FinancialNewsMedia
Exposures
COVID-19
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept...
Via
FinancialNewsMedia
Exposures
COVID-19
Intranasal Ketamine Garnering A lot of Attention as an Effective Treatment For Depression
November 23, 2021
Palm Beach, FL –November 23, 2021 – FinancialNewsMedia.com News Commentary – The COVID-19 pandemic is expected to have a significant positive impact on the growth of the global antidepressant market....
Via
FinancialNewsMedia
Exposures
COVID-19
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
November 17, 2021
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion...
Via
FinancialNewsMedia
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
October 27, 2021
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been...
Via
FinancialNewsMedia
Exposures
Product Safety
Rising Acceptance For Treating Mental Disorders is Fueling Strong Growth in Psychedelic Drugs Market
October 14, 2021
Palm Beach, FL –October 14, 2021 – FinancialNewsMedia.com News Commentary – Mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the...
Via
FinancialNewsMedia
Exposures
COVID-19
Strong Pipeline of Drugs for Treatment Of Psychotic Disorders Anticipated To Drive The Market Through 2028
October 11, 2021
Palm Beach, FL –October 11, 2021 – FinancialNewsMedia.com News Commentary – There is a high demand for more advanced products for the treatment and maintenance of severe mental disorders. Thus,...
Via
FinancialNewsMedia
SmallCapsDaily: Pasithea Therapeutics Emerges as a Major Player in the Biotech Industry
October 04, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.